Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Beta-sheet breaker peptide potentially effective against amyloidosis in Alzheimer's disease

July 24, 1998

Genentech stroke study terminated due to inability to demonstrate clinical benefit

July 23, 1998

Zelapar receives approval recommendation in U.K.

July 23, 1998

Phase III clinical trial results with galantamine suggest novel mechanism of action

July 23, 1998

Nortran initiates phase II trials for local anesthetic

July 23, 1998

New series of neuroprotective compounds described by Nippon Chemiphar

July 23, 1998

Inhaled analgesic available for licensing from BTG

July 23, 1998

Neurogen's epilepsy compound advances through clinical trials

July 22, 1998

Patient dosing begins in phase Ib trial of stroke drug from NPS

July 22, 1998

FDA clears SSRI for depression

July 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...